دورية أكاديمية
أعرض في EDS

Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.

التفاصيل البيبلوغرافية
العنوان: Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
المؤلفون: Guo X; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China.; Peking Union Medical College, Beijing, China., Liu M; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China., Hou H; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China., Liu S; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China., Zhang X; Department of Endocrinology, National Center of Gerontology, Beijing Hospital, Beijing, China., Zhang Y; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China., Wu P; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China., Pang C; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China., Wang J; Department of Urology, National Center of Gerontology, Beijing Hospital, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China. wangjy@bjhmoh.cn.
المصدر: International journal of clinical oncology [Int J Clin Oncol] 2019 Aug; Vol. 24 (8), pp. 957-965. Date of Electronic Publication: 2019 Mar 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : Tokyo : Springer-Verlag Tokyo
Original Publication: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996-
مواضيع طبية MeSH: Brachytherapy/*adverse effects , Neoplasms, Second Primary/*mortality , Prostatic Neoplasms/*radiotherapy , Urinary Bladder Neoplasms/*mortality, Adult ; Aged ; Aged, 80 and over ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasms, Second Primary/epidemiology ; Neoplasms, Second Primary/etiology ; Prognosis ; Prostatectomy/methods ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; SEER Program ; Survival Rate ; United States/epidemiology ; Urinary Bladder Neoplasms/epidemiology ; Urinary Bladder Neoplasms/etiology
مستخلص: Background: The impact of different radiotherapy modalities on the development and characteristics of second primary bladder cancers (BCa) and BCa-specific mortality (BCa-SM) remains unclear. Thus, we evaluated the incidence and biological behavior of subsequent BCa and related survival in patients who underwent radiation therapy for prostate cancer (PCa).
Methods: A total of 530,581 patients in the surveillance, epidemiology, and end results database with localized PCa between 1988 and 2013 were identified. PCa treatments included radical prostatectomy (RP), external beam radiotherapy (EBRT), radioactive implants (RI), and combined EBRT and RI (EBRI). A multivariable competing risk analysis based on a proportional sub distribution hazards model was used to determine the impact of different radiotherapy modalities on BCa incidence and specific mortality.
Results: Incidence of BCa was significantly high in patients treated with EBRT, RI, and EBRI vs. RP [sub distribution hazard ratio (SHR) 1.41, P < 0.001; SHR 1.58, P < 0.001; SHR 1.56, P < 0.001, respectively]. BCa following EBRT, RI, and EBRI were more commonly non-urothelial (3.3%, 2.9%, 3.3%, respectively, versus 1.2%) and T4 (3.5%, 6.1%, 5.0%, respectively, versus 1.6%) compared with RP. RI associated with a higher rate of BCa metastasis than RP (2.6% vs. 1.1%). Prior EBRT, RI, and EBRI increased BCa-SM (SHR 1.44, P = 0.001; SHR 1.21, P = 0.047; and SHR 1.42, P = 0.032, respectively).
Conclusions: Patients receiving radiotherapy for PCa have a higher risk of BCa. BCa after EBRT, RI, and EBRI is more likely to be non-urothelial, stage T4, and with increased BCa-SM. Prior RI associated with a higher rate of BCa metastasis.
References: Cancer Res. 1999 Aug 1;59(15):3606-9. (PMID: 10446970)
Swiss Med Wkly. 2004 Oct 30;134(43-44):645-9. (PMID: 15609208)
J Urol. 2006 Feb;175(2):739-43. (PMID: 16407042)
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7. (PMID: 16618572)
Cancer. 2006 Aug 15;107(4):721-8. (PMID: 16826584)
Radiat Res. 2007 Jul;168(1):1-64. (PMID: 17722996)
J Urol. 2008 Jan;179(1):91-5; discussion 95. (PMID: 17997457)
Urology. 2009 Apr;73(4):822-7. (PMID: 19193403)
Carcinogenesis. 2009 Nov;30(11):1821-31. (PMID: 19643821)
J Urol. 2010 May;183(5):1751-6. (PMID: 20299035)
Clin Exp Metastasis. 1991 Mar-Apr;9(2):77-104. (PMID: 2032423)
Urology. 2010 Dec;76(6):1430-3. (PMID: 20381130)
J Urol. 2010 Dec;184(6):2264-9. (PMID: 20952024)
J Natl Cancer Inst. 2010 Nov 3;102(21):1628-36. (PMID: 20975037)
Urol Oncol. 2013 Aug;31(6):857-61. (PMID: 21868262)
Urol Oncol. 2013 Nov;31(8):1628-34. (PMID: 22575239)
Eur Urol. 2013 Feb;63(2):234-41. (PMID: 22877502)
Semin Oncol. 2012 Oct;39(5):615-8. (PMID: 23040258)
Int J Environ Res Public Health. 2012 Dec 18;9(12):4744-59. (PMID: 23249860)
ISRN Urol. 2013 Jul 17;2013:405064. (PMID: 23956880)
Cancer. 2014 Sep 1;120(17):2735-41. (PMID: 24842808)
BMJ. 2016 Mar 02;352:i851. (PMID: 26936410)
J Natl Compr Canc Netw. 2016 May;14(5):509-19. (PMID: 27160230)
Eur Urol. 2017 Apr;71(4):618-629. (PMID: 27568654)
Ann Oncol. 2017 Feb 1;28(2):400-407. (PMID: 27831506)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Eur Urol. 2019 Feb;75(2):319-328. (PMID: 30293908)
Mutat Res. 1996 Jan 2;362(1):51-9. (PMID: 8538648)
فهرسة مساهمة: Keywords: Bladder cancer; Cancer-specific survival; Prostate cancer; Radiotherapy
تواريخ الأحداث: Date Created: 20190324 Date Completed: 20190903 Latest Revision: 20200225
رمز التحديث: 20231215
DOI: 10.1007/s10147-019-01427-9
PMID: 30903422
قاعدة البيانات: MEDLINE
الوصف
تدمد:1437-7772
DOI:10.1007/s10147-019-01427-9